Drug Digest: Changes and Trends in the Outsourcing Landscape
In this episode of Drug Digest, industry experts discuss the current outsourcing landscape in the post-COVID world and the changes the pandemic has enforced in the demand for outsourced bioprocessing services.
The outsourcing landscape has seen many changes in recent years coming out of the COVID pandemic. Driven by a burgeoning pipeline of clinical-phase therapeutic candidates and the practical need for more advanced analytics, the contract services industry is hustling to meet the expected growth of new, more complex therapeutics to hit the market over the next decade. In this episode of Pharmaceutical Technology®’s Drug Digest Video series, industry experts discuss the current outsourcing landscape in the post-COVID world and the changes the pandemic has enforced in the demand for outsourced bioprocessing services.
Interviews featuring
Eric S. Langer, president and managing partner, BioPlan Associates
Eric S. Langer has over 25 years experience in life sciences market assessment, valuation, marketing, management, and publishing. He been senior manager at biopharmaceutical supply companies and is an experienced biotechnology strategist. His team has advised hundreds of companies on marketing strategy development, valuation, pricing, and message strategy. Langer has also developed strategic plans based on quantitative analysis of market trends and buyer needs in valuation services, pricing, and analysis. He teaches graduate biotechnology marketing at Johns Hopkins University and biomedical valuation to the National Institutes of Health Graduate School.
Jordi Robinson, chief commercial officer, Navin Molecular
Jordi Robinson has nearly 30 years of experience in the pharma and specialty chemicals industries, and is currently chief commercial officer at Navin Molecular, with responsibilities for all customer-facing activities, including business development and project management. Prior to joining Navin Molecular, he worked for six and a half years leading the European business development team for global contract development and manufacturing organization, Asymchem Laboratories, and has also held commercial and technical roles at Robinson Brothers and Endeavour Speciality Chemicals. He has a bachelor’s degree in chemistry from the University of Central Lancashire, UK.
Sponsors
This episode of Drug Digest is sponsored by:
- Adare Pharma Solutions
- Coating Place Inc.
- LGM Pharma
- Nelson Labs
- Scorpius BioManufacturing
- Veltek Associates
About Drug Digest
Drug Digest is a tech talk video series with the Pharmaceutical Technology® editors, who interview industry experts to discuss the emerging opportunities, obstacles, and advances in the pharmaceutical and biopharmaceutical industry for the research, development, formulation, analysis, upstream and downstream processing, manufacturing, supply chain, and packaging of drug products.
Upcoming episodes
- June 2024: Analytics and Assays
- July 2024: Biopharma Drug Development and Manufacturing
- August 2024: Aseptic Processing and Manufacturing
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
